Table 4. Summary of Disease Management ROI Analysis for Asthma.
| Number | Average Sample Size for Intervention | Average Evaluation Period (Years) | Average Per Participant Cost and Savings
|
Average ROI
|
||
|---|---|---|---|---|---|---|
| Total Benefits/Costs | ||||||
| Study Design | Cost | Savings | ||||
| RCT (A) | 4 | 92 | 0.7 | $464.50 | $1,700.25 | 3.66 |
| RCT (B) | 1 | 49 | 1.5 | 1190.00 | 15,500.00 | 128.90 |
| CBA | 4 | 314 | 0.6 | 1,018.00 | 1,490.09 | 1.46 |
| Pre-Post | 3 | 226 | 0.6 | 2,715.15 | 8,461.75 | 3.12 |
| Total | 12 | 170 | 0.9 | 1,399.22 | 3,884.03 | 2.78 |
1
Australian dollar estimate.
NOTES: ROI is return on investment. RCT is randomized clinical trials. CBA is controlled, before and after study design. NA is not applicable.
SOURCE: Cornell University Institute for Policy Studies, 2004.